Sunday 18 October 2026
Export HUMA’s income statement to Excel — free account
Humacyte, Inc.
HUMA Healthcare Biotechnology
Humacyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, up 30.2% from fiscal 2022. In the quarter to June 2026, revenue grew 34.9%, EPS grew 33.3%, free cash flow grew 17.9% and total debt rose 437.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.43
0.01
−2.27%
Follow HUMA
| Dec '17 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 2 | — | — | — |
P/E ratio |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
P/S ratio |
— | — | 0.00 | 229.44 | 138.94 | — | — | 74.50 |
Altman Z-Score |
— | — | (6.66) | (0.98) | (2.00) | — | — | (10.48) |
P/FCF ratio |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (14.87) | (0.84) | (3.86) | — | — | (23.79) |
P/Operating CF |
— | — | (462.70) | (13.51) | (11.47) | — | — | (5.81) |
Beneish M-Score |
— | — | — | (1.31) | (1.71) | — | — | — |
P/B ratio |
— | — | 1.13 | 2.37 | 1.86 | — | — | 48.84 |
Price to Tangible BV |
— | — | 1.13 | 2.37 | 1.86 | — | — | 48.84 |
EV/Sales |
— | — | 0.00 | 89.28 | 66.94 | — | — | 80.36 |
EV/EBITDA |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
EV/Operating CF |
— | — | 0.00 | (1.39) | (1.47) | — | — | (1.56) |
EV/FCF |
— | — | 0.00 | (1.39) | (1.45) | — | — | (1.55) |
Quick Ratio |
— | — | 3.56 | 20.42 | 7.76 | 4.36 | 2.25 | 2.77 |
Current Ratio |
— | — | 3.69 | 20.75 | 7.88 | 4.52 | 2.40 | 3.69 |
Net Debt/EBITDA |
— | — | 0.30 | 2.46 | 1.51 | 0.70 | 0.29 | (0.12) |
Debt/Assets |
0.00% | 0.00% | 21.64% | 16.92% | 19.18% | 12.71% | 9.88% | 53.64% |
Debt/Equity |
— | — | (0.07) | 0.40 | 0.34 | 1.20 | (0.26) | 20.08 |
Asset Turnover |
— | 0.00 | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 |
Operating CF/Net income |
— | — | 0.84 | 3.07 | 5.94 | 0.66 | 0.66 | 2.57 |
Capex/Depreciation |
— | — | (0.03) | (0.02) | (0.11) | (0.28) | (0.22) | (0.12) |
Interest Coverage |
— | — | (29.34) | (18.68) | (13.64) | (15.16) | (12.33) | (9.61) |
| — | — | 58.32% | 23.21% | (10.01%) | (169.81%) | 760.17% | 164.78% | |
| — | 0.00% | (124.71%) | (13.47%) | (4.88%) | (66.63%) | (111.77%) | (32.12%) | |
ROIC |
— | — | 0.00% | 0.00% | (1,247.32%) | 0.00% | 0.00% | (449.67%) |
Return on Tangible Assets |
— | — | (93.44%) | (10.45%) | (7.27%) | (120.90%) | (291.75%) | (60.08%) |
Average Days of Receivables |
— | — | 27.66 | 50.86 | 7.23 | — | — | 78.98 |
Research and Development Expense of Revenue |
— | — | 3,626.96% | 4,856.77% | 4,042.17% | 0.00% | 0.00% | 3,400.49% |
Selling, General and Administrative Expense of Revenue |
— | — | 805.70% | 1,673.00% | 1,462.17% | 0.00% | 0.00% | 1,529.49% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
— | — | 314.82% | 803.33% | 395.14% | 0.00% | 0.00% | 478.56% |
Graham Net Nets |
— | — | (0.07) | 0.22 | 0.31 | — | — | (0.30) |
Graham Number |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Earnings Yield |
— | — | (0.20%) | (91.86%) | (5.69%) | — | — | (20.83%) |
Free Cash Flow Yield |
— | — | 0.00% | (28.09%) | (33.19%) | — | — | (69.76%) |
Revenue per Share |
— | — | 0.26 | 0.03 | 0.02 | 0.00 | 0.00 | 0.01 |
Operating CF per Share |
— | — | (9.64) | (2.03) | (0.69) | (0.71) | (0.83) | (0.66) |
Capex per Share |
— | — | (0.05) | (0.01) | (0.01) | (0.02) | (0.01) | (0.01) |
Free Cash Flow per Share |
— | — | (9.68) | (2.04) | (0.70) | (0.73) | (0.84) | (0.67) |
Cash per Share |
— | — | 6.93 | 5.64 | 1.47 | 0.78 | 0.38 | 0.32 |
Shareholders Equity per Share |
— | — | (60.76) | 3.06 | 1.13 | 0.13 | (0.44) | 0.02 |
Interest Debt per Share |
— | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
— | — | (60.76) | 3.06 | 1.13 | 0.13 | (0.44) | 0.02 |
Free Cash Flow |
— | — | (55.84) | (81.41) | (72.18) | (75.58) | (99.69) | (105.93) |
Working Capital |
— | — | 30.22 | 218.29 | 134.63 | 64.84 | 27.91 | 49.42 |
Capital Expenditures |
— | — | (0.27) | (0.22) | (1.05) | (2.28) | (1.57) | (0.88) |
Net Current Asset Value |
— | — | (415.56) | 64.98 | 66.83 | (31.40) | (142.68) | (45.46) |
EV/EBIT |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Capex to Sales |
— | — | 0.18 | 0.17 | 0.67 | 0.00 | 0.00 | 0.43 |
Price to Operating Income |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
| Other line items | ||||||||
Depreciation/Fixed assets |
— | — | 0.20 | 0.26 | 0.32 | 0.31 | 0.31 | 0.40 |
Cash ROIC |
— | — | 19.43% | (20.55%) | (23.43%) | (68.53%) | (1,693.17%) | (91.30%) |
Accounts Receivable Turnover |
— | — | 10.32 | 8.74 | 15.12 | — | — | 8.64 |
Accounts Payable Turnover |
— | — | 3.86 | 3.79 | 4.48 | 0.00 | 0.00 | 1.96 |
Inventory Turnover |
— | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 |
Average Days of Payables |
— | — | 98.44 | 92.27 | 70.52 | 0.00 | 0.00 | 203.30 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | 0.00 | — | — | 511.23 |
Average Receivables |
— | — | 0.14 | 0.14 | 0.10 | — | — | 0.24 |
Average Payables |
— | — | 2.18 | 2.18 | 1.84 | 4.04 | 5.49 | 4.95 |
Average Assets |
— | 0.00 | 53.34 | 196.61 | 245.42 | 166.26 | 133.05 | 127.12 |
Average Common Equity |
— | — | (114.07) | (114.07) | 119.55 | 65.24 | (19.56) | (24.78) |
Columns are period end dates